{"id":57773,"date":"2024-05-30T18:15:00","date_gmt":"2024-05-30T16:15:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-the-launch-of-an-employee-shareholding-plan\/"},"modified":"2024-07-23T10:43:28","modified_gmt":"2024-07-23T08:43:28","slug":"ipsen-announces-the-launch-of-an-employee-shareholding-plan","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-the-launch-of-an-employee-shareholding-plan\/","title":{"rendered":"Ipsen announces the launch of an employee shareholding plan"},"content":{"rendered":"\n\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Ipsen announces the launch of an employee shareholding plan<\/strong><\/p>\n

PARIS, FRANCE, 30 May 2024 – <\/strong>Ipsen (Euronext: IPN; ADR: IPSEY) today announced the launch of an employee shareholding plan. The fourth transaction in the last eight years aims to involve Ipsen’s employees more closely, both in France and abroad, in the Group’s development and performance. It will be launched in 23 countries.<\/p>\n

This plan, for employee only, will be carried out through the sale of existing shares reserved for members of a Company savings plan. The sale of existing shares will be capped to a number of shares representing a maximum of 1% of the Company’s share capital. <\/p>\n

Upon delegation of the Board of Directors, the Chief Executive Officer has set the subscription price of a share in the context of this transaction on 30 May 2024. The subscription price of a share corresponds to the average opening prices of the Ipsen share on Euronext Paris during the twenty (20) trading days preceding the decision of the Chief Executive Officer, less a 20% discount. The subscription price is \u20ac95.54.<\/p>\n

Beneficiaries of the Offering<\/em><\/p>\n

The offering is carried out pursuant to Articles L. 3332-18 et seq. of the French Labour Code, within the framework of Ipsen’s Group Savings Plan (\u201cPEG<\/em>\u201d) and International Group Savings Plan. Ipsen employees will benefit from an employer matching contribution.<\/p>\n

It is intended for the Group employees with at least three months’ seniority and who are located in the following countries: Australia, Belgium, Brazil, Canada, China, Colombia, Czech Republic, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Singapore, South Korea, Spain, Sweden, Taiwan, the U.K. and the U.S.<\/p>\n

Former retired and pre-retired employees who have retained assets in the GSP since leaving the Group are also eligible to participation in the transaction, without the benefit of the employer matching contribution.<\/p>\n

The shares subscribed to, in registered form or through a Fonds Commun de Placement d\u2019Entreprise<\/em> (\u201cFCPE<\/em>\u201d), will be locked-up for a period of (5) years, in accordance with the regulations governing employee savings plans, except in the case of authorized early exit events.<\/p>\n

Indicative timetable of the transaction<\/em><\/p>\n

Setting of the subscription price: 30 May 2024
Subscription period: from 5 June to 19 June 2024
Settlement-delivery of the offering: expected on 30 July 2024<\/p>\n

The shares purchased within the framework of the transaction will be Ipsen ordinary shares and will be fully assimilated to existing Ipsen shares listed on Euronext Paris (ISIN code: FR0010259150).<\/p>\n

This press release does not constitute an offer to sell or the solicitation of an offer to subscribe for Ipsen shares. The Ipsen share offering is strictly reserved for members of a Group employee savings plan and will only be implemented in countries where such an offering has been registered with or notified to the competent local authorities and\/or following approval of a prospectus by the competent local authorities, or in consideration of an exemption from the obligation to prepare a prospectus or to register or notify the offering.<\/p>\n

ENDS<\/strong><\/p>\n

About Ipsen <\/strong><\/p>\n

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. <\/p>\n

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries.<\/p>\n

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.<\/p>\n

Ipsen contacts <\/strong><\/p>\n

Investors<\/strong><\/p>\n